Eli Lilly and Company (NYSE:LLY) Downgraded by Wall Street Zen to “Buy”

Wall Street Zen downgraded shares of Eli Lilly and Company (NYSE:LLY) from a strong-buy rating to a buy rating in a research note issued to investors on Saturday morning.

Other equities analysts have also issued research reports about the stock. Leerink Partners set a $1,234.00 price target on shares of Eli Lilly and Company in a research report on Monday, January 5th. Rothschild & Co Redburn boosted their target price on shares of Eli Lilly and Company from $775.00 to $830.00 and gave the company a “neutral” rating in a research note on Monday, January 26th. JPMorgan Chase & Co. raised their price target on shares of Eli Lilly and Company from $1,050.00 to $1,150.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 18th. Erste Group Bank upgraded Eli Lilly and Company from a “hold” rating to a “buy” rating in a research note on Tuesday, October 14th. Finally, CICC Research increased their price objective on Eli Lilly and Company from $801.00 to $1,060.00 and gave the company a “neutral” rating in a report on Thursday, November 13th. Four analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and five have issued a Hold rating to the stock. According to MarketBeat, Eli Lilly and Company currently has an average rating of “Moderate Buy” and a consensus price target of $1,162.75.

Eli Lilly and Company Stock Performance

Shares of LLY opened at $1,037.84 on Friday. The stock has a 50 day moving average of $1,056.87 and a 200 day moving average of $889.48. The company has a market capitalization of $981.15 billion, a price-to-earnings ratio of 50.77, a PEG ratio of 0.77 and a beta of 0.35. Eli Lilly and Company has a 12 month low of $623.78 and a 12 month high of $1,133.95. The company has a current ratio of 1.55, a quick ratio of 1.24 and a debt-to-equity ratio of 1.71.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Thursday, October 30th. The company reported $7.02 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.42 by $0.60. Eli Lilly and Company had a return on equity of 109.52% and a net margin of 30.99%.The firm had revenue of $17.60 billion during the quarter, compared to the consensus estimate of $16.09 billion. During the same quarter in the prior year, the company earned $1.18 EPS. The business’s revenue for the quarter was up 53.9% on a year-over-year basis. As a group, sell-side analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Friday, February 13th will be issued a $1.73 dividend. The ex-dividend date of this dividend is Friday, February 13th. This is an increase from Eli Lilly and Company’s previous quarterly dividend of $1.50. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.7%. Eli Lilly and Company’s dividend payout ratio is 29.35%.

Institutional Trading of Eli Lilly and Company

A number of institutional investors have recently added to or reduced their stakes in LLY. Secured Retirement Advisors LLC boosted its stake in Eli Lilly and Company by 8.8% in the 4th quarter. Secured Retirement Advisors LLC now owns 1,846 shares of the company’s stock worth $1,984,000 after purchasing an additional 150 shares during the period. Sigma Planning Corp increased its position in shares of Eli Lilly and Company by 5.1% during the fourth quarter. Sigma Planning Corp now owns 17,060 shares of the company’s stock valued at $18,445,000 after buying an additional 825 shares during the period. Belleair Asset Management LLC purchased a new stake in shares of Eli Lilly and Company in the fourth quarter worth about $346,000. Citizens Financial Group Inc. RI boosted its position in shares of Eli Lilly and Company by 0.9% in the fourth quarter. Citizens Financial Group Inc. RI now owns 74,935 shares of the company’s stock valued at $80,531,000 after acquiring an additional 648 shares during the period. Finally, North Star Investment Management Corp. boosted its position in shares of Eli Lilly and Company by 4.4% in the fourth quarter. North Star Investment Management Corp. now owns 8,546 shares of the company’s stock valued at $9,185,000 after acquiring an additional 363 shares during the period. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Trending Headlines about Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: CEO David Ricks said impending Medicare coverage for obesity drugs could “change the game” for the launch of Lilly’s oral obesity candidate orforglipron, signaling a major commercial catalyst if access and reimbursement broaden this year. Eli Lilly CEO says Medicare coverage of obesity drugs could ‘change the game’ for upcoming pill launch
• Positive Sentiment: Lilly announced a $3.5 billion Lehigh Valley (PA) injectable manufacturing plant to produce next‑gen weight‑loss drugs (including retatrutide), expanding U.S. capacity and creating ~2,800 jobs — a material long‑term supply and growth investment. Eli Lilly to build $3.5 billion Pennsylvania plant in US manufacturing push
• Positive Sentiment: TD Cowen raised its price target sharply to $1,250 and maintained a buy rating, providing analyst backing that can support further upside and investor confidence. TD Cowen adjusts price target on Eli Lilly and Co to $1,250
• Positive Sentiment: Lilly expanded its R&D and partnering footprint with a ~ $1.93B deal with Repertoire (autoimmune therapies) and other gene‑editing/oncology investments, diversifying future growth drivers beyond GLP‑1s. Lilly signs up to $1.93 billion deal with Repertoire for autoimmune therapies
• Neutral Sentiment: Competitor Novo Nordisk ramped U.S. advertising for Wegovy/Ozempic after prior supply constraints eased, outspending Lilly — a sign of intensifying marketing competition in obesity that could pressure share gains or require higher promotional spend. Novo Nordisk Outspends Eli Lilly On Wegovy, Ozempic Ads After Supply Crunch Eases
• Negative Sentiment: The FDA action date for Lilly’s oral weight‑loss pill orforglipron was moved to April 10 (Q2), delaying potential revenue contribution and near‑term clarity on approval — a timing risk that can cap upside until the new decision date. FDA Decision on Eli Lilly’s Weight Loss Pill Delayed to Q2

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.